



SEPTEMBER 2026

# Investor Deck

VDMT-2697-AUG-2026



[veradigm.com](https://veradigm.com)

# Disclaimer and Forward-Looking Statement Information

---

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the Company's preliminary estimated unaudited 2025 financial information, the Company's anticipated revenue growth and future financial performance, the Company's business and growth strategies, including its "reset, recover, reignite" strategy, the Company's product portfolio optimization and anticipated product roadmap, and the Company's anticipated SEC filings and relisting on a national securities exchange. These forward-looking statements are based on the current beliefs and expectations of the Company's management with respect to future events, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as "future," "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "will," "would," "could," "continue," "can," "may," "look forward," "aims," "hopes," and "seeks" and similar terms, although not all forward-looking statements contain such words or expressions. Actual results could differ significantly from those set forth in the forward-looking statements.

Important factors that could cause actual results to differ materially from those expressed or implied in these forward-looking statements include, but are not limited to: the preliminary and unaudited nature of the Company's estimated 2025 financial information, which remains subject to the completion of the Company's year-end close, review and audit procedures and could change materially; the Company's ability to complete its delinquent periodic reports and to become and remain current in its SEC reporting obligations; the risk that the Company's Common Stock is not relisted on a national securities exchange, or, if relisted, does not remain listed or does not develop an active trading market; the Company's ability to successfully execute its "reset, recover, reignite" strategy, including product portfolio optimization, investment in and scaling of higher-growth solutions and deeper alignment with independent physician practices; the risk that operational, technological and organizational changes, including workforce optimization and a centralized global operating structure, prove more complex, costly or time-consuming than expected or disrupt operations or customer relationships; the Company's ability to maintain and expand relationships with existing customers; intense competition and rapid technological change in the markets for the Company's products and services, including with respect to AI and machine learning; risks associated with the Company's expanding use of AI; cybersecurity incidents, IT system failures and network disruptions affecting protected health information or other sensitive data; and the other factors discussed in Part I, Item 1A, "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal years ended December 31, 2023 and December 31, 2024 filed with the SEC on May 26, 2026, and in the Company's subsequent filings with the SEC. The Company does not undertake to update any forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes over time, except as required by law.

We are a healthcare data and technology company connecting providers, payers and life science companies

**\$584-589 M**

Expected Revenue  
in 2025

**2,300**

Associates

**148 M**

Patient Records

**1.7 B**

Patient Visits

**\$60 B**

Addressable Market

WE SERVE THREE SEGMENTS CONNECTED BY OUR HEALTH NETWORK ARCHITECTURE



### Providers

Leading EHR, practice management and revenue cycle provider for independent physician groups



### Payers / Health Plans

Risk adjustment, quality reporting and care-gap closure at scale



### Life Sciences

Real-world data, clinical evidence products and point-of-care media



## **We are a Leader in Healthcare Technology**

**We empower independent physician practices with technology that positions us at the intersection of clinical workflows & data monetization**

- Our highly recurring Provider market footprint enables us to leverage capabilities across the Payer Health and Life Sciences markets



## **Veradigm Health Network Architecture**

**Provides independent practices a single real-time view of their clinical, financial, and operational performance**

- Products across all three segments feed one connected data layer that powers our AI capabilities



## **Reset, Recover, Reignite**

**Our strategy is in place to accelerate top-line growth and improve profitability beginning in 2026**

- Our transformation efforts aimed at simplification & innovation are helping to fuel our flywheel



## **Audit and Filings**

**Our recent filings and what we expect for 2026**

- Recently filed our 2023 and 2024 10K. 2025 audit underway
- An expected 10K filing in the later part of 2026
- Expect to relist our shares on a national exchange once we are current with our filings



## **Growth Initiatives**

**Maintain a strong balance sheet to support our growth initiatives**

- \$120 million in cash and cash equivalents at year end 2025
- Debt of \$75 million

**We are in a strong position to drive sustainable growth and create long-term shareholder value**

# Our Transformation

## Where We Have Been

### NO REVENUE GROWTH

Flat, +/-0% since 2022, even with M&A and strategic investments

### POOR CUSTOMER RETENTION

- Customer dissatisfaction, notably in the Provider EHRs: Estimated gross revenue retention (GRR) of 82%

### SILOED, COMPLEX PRODUCT & PLATFORM

Most product partners erode gross margin and add complexity

### HOLDING COMPANY WITH SILOED BUSINESS UNIT WORKFORCE

500+ vendor relationships and 2,000+ POs; three Salesforce instances

## Where We Are Going

### GROWTH TO ACCELERATE BEGINNING IN 2026

- Growth 'bets' within each segment, funded and road mapped
- Unify RevOps, enterprise systems, sales forecast and close process

### IMPROVED CUSTOMER RETENTION

- Enterprise-wide NPS uplift plan with OKR to improve NPS by +10
- New strategic account planning, new client management model, and revised incentive framework

### ONE CONNECTED PLATFORM

- Bring together development, AI leadership talent, and infrastructure
- Rationalize product & solution portfolio: invest, sustain, sunset/sell while rethinking product partnerships

### PEOPLE: 'ENTREPRENEURIAL' OPERATING SYSTEM

- OKRs at the individual level (in Workday) for 100% of team

# Veradigm Management Team

WE HAVE THE RIGHT  
TEAM IN PLACE  
TO EXECUTE ON  
OUR STRATEGY



**Don Trigg**  
CHIEF EXECUTIVE OFFICER



**Tehsin Syed**  
CHIEF TECHNOLOGY  
& PRODUCT OFFICER



**Troy Tetzlaff**  
SVP REVENUE  
OPERATIONS



**Tally Baker**  
CHIEF HUMAN RESOURCES  
OFFICER



**Eric Jacobson**  
INTERIM GENERAL  
COUNSEL



**Jonathan  
Vipperman**  
SVP AND GM PROVIDER



**Jay  
Bhattacharyya**  
SVP AND GM PAYER



**Christian  
Greyenbuhl**  
CHIEF FINANCIAL OFFICER

SELECTED PRIOR  
EXPERIENCE



UNITEDHEALTH GROUP®



# Veradigm Board of Directors

OUR BOARD OF  
DIRECTORS BRINGS A  
LEVEL OF OVERSIGHT  
AND EXPERIENCE TO  
HELP MANAGEMENT  
EXECUTE ON ITS  
GROWTH STRATEGIES



**Don Trigg**  
CHIEF EXECUTIVE OFFICER




**Vinit Asar<sup>2</sup>**  
DIRECTOR



**Bruce Felt<sup>3</sup>**  
DIRECTOR



**Susan Rodriguez**  
DIRECTOR



**Jonathan Sacks**  
DIRECTOR



**Louis Silverman<sup>1</sup>**  
DIRECTOR



**Dave Stevens<sup>4</sup>**  
DIRECTOR




**Carol Zierhoffer**  
DIRECTOR

- (1) Chairman of the Board
- (2) Chairman Nominating and Governance Committee
- (3) Chairman Audit Committee
- (4) Chairman Compensation Committee

# Veradigm Addresses a Large Market Opportunity With Current and Adjacent Products

Total Addressable Market of ~\$60B



Column width proportional to each segment's total TAM; each column indexed to 100%.

**Note:** Incremental SAM and incremental TAM include current and adjacent products | Billions of USD

**Source:** L.E.K. research and analysis

# Reset. Recover. Reignite.



# Reignite Growth

---

## WE WIN WHEN WE HAVE:

**Strong alignment with independent physician practices**


**A deep, high ROI provider solution footprint (Revenue Cycle, Practice Ops)**

**Payer and Life Sciences clients can collaborate effectively with providers**

**When providers want to collaborate with Payers and Life Sciences, we make it frictionless and easy for them**

**Driving to reaccelerate long-term profitable growth**

# We Operate in Three Segments Connected by our Health Network Architecture



# Provider Solutions Overview

## EHRs

Veradigm Suite (EHR & PM) for mid-size practices

Practice Fusion for small practices

## Revenue Cycle

Veradigm Revenue Cycle Services

Veradigm Payerpath

## Documentation & Coding

Veradigm Ambient Scribe

Veradigm Coding Services

## Patient Engagement

Veradigm FollowMyHealth portal

Mobile Patient Experience

## Prescribing & Connectivity

Veradigm ePrescribe

Veradigm DORN – Lab Offering

## Care Gap & Quality

Veradigm Payer Insights

Veradigm eChart Courier

Enabling Independent practices to remain independent and thrive in a consolidating market




# Provider | Representative VEHR Clients

|                                                                                   |                                                                                    |                                                                                      |                                                                                      |                                                                                      |
|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|  |   |   |   |   |
|                                                                                   |   |   |   |   |
|                                                                                   |  |  |  |  |

We have a leading position with small- to medium-size independent physician practices




# Payer Solutions | Leveraging Provider Data at Scale



Maximize financial performance and clinical outcomes for health plans and MCOs

# Life Sciences | Leveraging Provider Data at Scale<sup>(1)</sup>



Serving pharmaceutical and biotech companies with real-world data, evidence generation, and point of care advertising

(1) Bold indicates current offerings



# Veradigm AI Product Strategy

---

## Before the visit

Agentic intake and insurance check

Predictive no show risk

Schedule optimization

## During the visit

Ambient clinical documentation

Agentic payer formulary check

Agentic prior authorization

## After the visit

Agentic documentation and coding


Agentic referral management

Agentic chronic disease management

**Agents and AI embedded seamlessly to increase our clients' efficiency**

# Veradigm Health Network Architecture

Products across all three segments feed one connected data layer that powers our AI capabilities



# Health Network Architecture and Agents Working Together

---

## THE SYSTEM OF WORK

### Health Network Architecture

**The connection layer.**

One unified data layer across your Veradigm products.

+

### Agentic AI

**The action layer.**

Review charts, draft documentation, build claims, surface risks, take action.

SYSTEMS OF RECORD   EHR | Practice Management | Payerpath | Revenue Cycle Management | FollowMyHealth

# Veradigm Investment Summary



## Reset, Recover, + Reignite

We are executing on our Reset, Recover and Reignite plan.



## Independent Physicians

We will continue to focus on our core markets including serving independent physician groups

- We'll do this while augmenting growth in the payer and life science segments.



## Veradigm Health Network

This architecture is central to our growth strategy.

- Provides independent practices a single real-time view of their clinical, financial, and operational performance
- Helps close a capability gap that has historically separated independent practices from large health systems.



## Artificial Intelligence

Our provider clients are looking to us to bring AI capabilities to their practices

- To create workflow efficiencies in their practices as they desire to stay independent.



## Financial Discipline

Maintain this while making the appropriate investments

- To leverage our capabilities to support our long-term sustainable growth model.

**The company is in a strong position to create shareholder value**



veradigm®

TRANSFORMING HEALTH, *Insightfully*



[veradigm.com](https://veradigm.com)